As of this afternoon, the FDA Drug Shortage List is showing that the shortage of tirzepatide injection is “resolved.” Pharmacies must immediately cease preparing and dispensing compounded copies of Mounjaro and Zepbound. read more →
Now Eli Lilly is trying to "convince" people who have used compounded versions of tirzepatide to share their confidential medical records with the company. read more →
A settlement has been reached in a lawsuit brought by Evexias et al against FDA over the agency's 2023 addition of a number of substances to Category 2 of the 503A bulks list. read more →
David Rochefort of Revelation Pharma is this year's recipient of the George and Lucy Malmberg Compounding Advocacy Champion award — APC’s highest honor. read more →